Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data).
We conducted a meta-analysis on 6 studies in 2,963 patients who had coronary artery disease and received a sirolimus-eluting stent or a bare metal stent for revascularization. Compared with bare metal stents, sirolimus-eluting stents did not appear to increase the risk for thrombosis up to 13.5 months after coronary intervention (risk ratio 0.49, 95% confidence interval 0.22 to 1.12, p = 0.09).
Bavry
Anthony A
AA
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Kumbhani
Dharam J
DJ
Helton
Thomas J
TJ
Bhatt
Deepak L
DL
D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D003327:Coronary Disease; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy; D003328:Coronary Thrombosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D011183:Postoperative Complications; D011859:Radiography; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects* / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus